What is Cynosure?
Cynosure is a prominent developer and manufacturer of energy-based aesthetic and medical treatment systems. The company's diverse portfolio includes leading applications for hair removal, skin revitalization, scar reduction, gynecological health, and body contouring. These innovative products are utilized globally by practitioners, physicians, and aesthetic business owners, enabling them to enhance their service offerings and provide advanced treatments to patients. The company's focus on innovation positions it as a key player in the rapidly evolving medical aesthetics market.
How much funding has Cynosure raised?
Cynosure has raised a total of $135M across 2 funding rounds:
Stock Offering
$75M
Private Equity
$60M
Stock Issuance/Offering (2005): $75M, investors not publicly disclosed
Private Equity (2022): $60M led by Clayton, Dubilier & Rice
Key Investors in Cynosure
Clayton, Dubilier & Rice
Clayton, Dubilier & Rice is a private equity firm known for its strategic approach to building businesses. Their involvement suggests a focus on operational improvements and long-term value creation within Cynosure's established market.
What's next for Cynosure?
The recent major strategic investment signals a new phase of growth and development for Cynosure. This capital infusion is expected to fuel further innovation in their treatment applications, potentially expanding their market reach and enhancing their technological capabilities. The company's trajectory suggests a focus on scaling operations and solidifying its leadership position through continued investment in research and development, aiming to meet the increasing global demand for advanced aesthetic and medical procedures.
See full Cynosure company page
